2,964
Views
4
CrossRef citations to date
0
Altmetric
Cardiovascular

Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia

, ORCID Icon, , &
Pages 77-86 | Received 25 Nov 2021, Accepted 16 Dec 2021, Published online: 10 Jan 2022

References

  • Otto CM, Prendergast B. Aortic-Valve stenosis — from patients at risk to severe valve obstruction. Massachusetts Med Soc. 2014;371:744–756. https://doi.org/10.1056/NEJMra1313875.
  • Go AS, Mozaffarian D, Roger VL. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.,
  • Lloyd-Jones D, Adams RJ, Brown TM. et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–954.,
  • Varadarajan P, Kapoor N, Bansal RC, et al. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006;82(6):2111–2115.
  • Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(23):2440–2492.,
  • Coylewright M, Palmer R, O’Neill ES, et al. Patient-defined goals for the treatment of severe aortic stenosis: a qualitative analysis. Health Expect. 2016;19(5):1036–1043.
  • Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. The Lancet. 2006;368(9540):1005–1011.
  • De Sciscio P, Brubert J, De Sciscio M, et al. Quantifying the shift toward transcatheter aortic valve replacement in low-risk patients: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(6):e003287.
  • Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24(13):1231–1243.
  • Alatawi FO, Abuelatta RA, AlAhmedi AB, et al. Clinical outcomes with transcatheter aortic valve implantation at a single cardiac center in Saudi Arabia. Ann Saudi Med. 2018;38(3):167–173.
  • Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–2198.
  • Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–1695.
  • Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–2484.
  • Reynolds MR, Magnuson EA, Wang K, et al. Health-Related quality of life after transcatheter or surgical aortic valve replacement in High-Risk patients with severe aortic stenosis: results from the PARTNER (placement of AoRTic TraNscathetER valve) trial (cohort a). J Am Coll Cardiol. 2012;60(6):548–558.
  • Arnold SV, Reynolds MR, Wang K, et al. Health status after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis at increased surgical risk: results from the CoreValve US pivotal trial. JACC Cardiovasc Interv. 2015;8(9):1207–1217.,
  • EuroPCR. 2015. The SAPIEN 3 Trials – One Year Outcomes | Radcliffe Cardiology [Internet]; [cited 2021 Sep 15]. Available from: https://www.radcliffecardiology.com/video-index/europcr-2015-sapien-3-trials-one-year-outcomes.
  • Herrmann HC, Thourani VH, Kodali SK, et al. One-Year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in High-Risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–140.
  • Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37(28):2252–2262.
  • Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64(21):2235–2243.
  • Romano M, Frank D, Cocchieri R, et al. Transaortic transcatheter aortic valve implantation using SAPIEN XT or SAPIEN 3 valves in the ROUTE registry†. Interact Cardiovasc Thorac Surg. 2017;25(5):757–764.
  • Cocchieri R, Petzina R, Romano M, et al. Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTE†. Eur J Cardiothorac Surg. 2019;55(4):737–743.
  • Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218–2225.
  • Kodali S. SAPIEN 3 transcatheter aortic valve replacement compared with surgery in intermediate-risk patients: a propensity-matched analysis of 5-year outcomes [Internet]. TCTMD.com. 2020; [cited 2021 Sep 15]. Available from: https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients-0.
  • Tuzcu EM. Real world outcomes of TAVR with the SAPIEN 3 valve in intermediate risk patients: comparison of data form the TVT registry with PARTNER S3 studies. Paris, France; 2018.
  • Edwards Lifesciences. A prospective, randomized, controlled, multi-center study to establish the safety and effectiveness of the SAPIEN 3 Transcatheter heart valve in low risk patients who have severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement [Internet]. clinicaltrials.gov. 2021; [cited 2021 Sep 13]. Report No.: NCT02675114. Available from: https://clinicaltrials.gov/ct2/show/NCT02675114.
  • Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve replacement with a Balloon-Expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705.
  • Waksman R, Rogers T, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72(18):2095–2105.
  • Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–1161.,
  • Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health. 2007;10(5):336–347.
  • Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807–827.
  • van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33–40.
  • Al-Omar HA, Aljuffali IA, Solà-Morales O. Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: results from a capacity building, multi-stakeholder workshop. Saudi Pharm J. 2021;29(9):946–954.
  • Al-Omar HA, Attuwaijri AA, Aljuffali IA. Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia. Saudi Pharm J. 2020;28(6):662–668.
  • World Health Organization. Global Health Observatory, Life tables [Internet]. WHO. World Health Organization; [cited 2021 Sep 21]. Available from: https://apps.who.int/gho/data/view.main.61440?lang=en.
  • Chello C, Lusini M, Nenna A, et al. Deep sternal wound infection (DSWI) and mediastinitis after cardiac surgery: current approaches and future trends in prevention and management. Surg Technol Int. 2020;36:212–216.
  • Hawkins RB, Mehaffey JH, Charles EJ, et al. Cost-effectiveness of negative pressure incision management system in cardiac surgery. J Surg Res. 2019;240:227–235.
  • Schiraldi L, Jabbour G, Centofanti P, et al. Deep sternal wound infections: evidence for prevention, treatment, and reconstructive surgery. Arch Plast Surg. 2019;46(4):291–302.
  • Tegnell A, Arén C, Ohman L. Coagulase-negative staphylococci and sternal infections after cardiac operation. Ann Thorac Surg. 2000;69(4):1104–1109.
  • Ridderstolpe L, Gill H, Granfeldt H, et al. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg. 2001;20(6):1168–1175.
  • Sjögren J, Malmsjö M, Gustafsson R, et al. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg. 2006;30(6):898–905.
  • Heilmann C, Stahl R, Schneider C, et al. Wound complications after median sternotomy: a single-centre study. Interact Cardiovasc Thorac Surg. 2013;16(5):643–648.
  • Shehada S-E, Wendt D, Peters D, et al. Infections after transcatheter versus surgical aortic valve replacement: mid-term results of 200 consecutive patients. J Thorac Dis. 2018;10(7):4342–4352.
  • Tirado-Conte G, Freitas-Ferraz AB, Nombela-Franco L, et al. Incidence, causes, and impact of in-Hospital infections after transcatheter aortic valve implantation. Am J Cardiol. 2016;118(3):403–409.
  • Falcone M, Russo A, Mancone M, et al. Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. Clin Microbiol Infect. 2014;20(8):758–763.
  • Nakamura M, Chakravarty T, Jilaihawi H, et al. Complete percutaneous approach for arterial access in transfemoral transcatheter aortic valve replacement: a comparison with surgical cut-down and closure. Catheter Cardiovasc Interv. 2014;84(2):293–300.
  • Wu Y-C, Zhang J-F, Shen W-F, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: a meta analysis. Chin Med J. 2013;126(6):1171–1177.
  • Shehada S-E, Elhmidi Y, Öztürk Ö, et al. Transcatheter versus surgical aortic valve replacement after previous cardiac surgery: a systematic review and meta-analysis. Cardiol Res Pract. 2018;2018:1–11.
  • Klein H, Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ. 2017;20(6):640–645.
  • Tam DY, Azizi PM, Fremes SE, et al. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2020;2020:qcaa058.
  • Doble B, Blackhouse G, Goeree R, et al. Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. J Thorac Cardiovasc Surg. 2013;146(1):52–60.e3.
  • Baron SJ, Wang K, House JA. et al. Cost-Effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Circulation. 2019;139(7):877–888.
  • Hersi AS, Osenenko KM, Kherraf SA, et al. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia. Ann Saudi Med. 2019;39(4):265–278.
  • Tarride J-E, Luong T, Goodall G, et al. A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res. 2019;11:477–486.
  • Zhou J, Liew D, Duffy SJ, et al. Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. Int J Cardiol. 2019;294:17–22.
  • Shah KK, Elder D, Nguyen MTH, et al. Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement for aortic stenosis (SAVR): a cost-comparison study. Heart Lung Circ. 2021;2021:S1443-9506(21)00550-3.
  • Health Information and Quality Authority. Health Technology Assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications [Internet]. Health Information and Quality Authority; 2019; [cited 2021 Sep 23]. Available from: https://www.hiqa.ie/sites/default/files/2019-12/TAVI_HTA.pdf.
  • Norwegian Institute of Public Health. Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups [Internet]. Norwegian Institute of Public Health. 2021; [cited 2021 Sep 23]. Available from: https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/.
  • Gilard M, Eltchaninoff H, Iung B, et al. Cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value in Health. 2021;22(4):289–296. https://www.valueinhealthjournal.com/article/S1098-3015(21)01786-1/fulltext.
  • Al-Senani F, Al-Johani M, Salawati M, et al. A national economic and clinical model for ischemic stroke care development in Saudi Arabia: a call for change. Int J Stroke. 2019;14(8):835–842.
  • Alharthy A, Karakitsos D. King saud medical city intensive care unit: a critical and cost-focused appraisal. Saudi Crit Care J. 2019;3(1):19–23.
  • Altowaijri A, Alshehri N, Balkhi B, et al. PCV50 economic burden of major cardiovascular diseases and ischemic stroke in Saudi Arabia: a cost of illness study. Value in Health. 2020;23:S495–S496.
  • Johnston KM, Osenenko KM, Qatami L, et al. Health care resource utilization and costs in individuals with atrial fibrillation in United Arab Emirates and kingdom of Saudi Arabia: a retrospective cohort study. Int J Int Med. 2015;4:17–25.
  • Independent Hospital Pricing Authority. Development of the admitted care classifications: Public Consultation [Internet]. Independent Hospital Pricing Authority; 2021; [cited 2021 Sep 23]. Available from: https://www.ihpa.gov.au/sites/default/files/development_of_the_admitted_care_classifications_pdf_0.pdf.
  • Rai D, Tahir MW, Chowdhury M, et al. Transcatheter aortic valve replacement same-day discharge for selected patients: a case series. Eur Heart J Case Rep. 2021;5(2):ytaa556.
  • Butala N. Economics of minimalist TAVR: the 3M TAVR economic study. Boston, USA; 2021.
  • Haute Autorité de Santé. EDWARDS SAPIEN 3, bioprothèse valvulaire aortique implantée par voie transfémorale (système COMMANDER) [Internet]. Commission Nationale d’Evaluation des Dispositifs Medicaux et des Technologies de Sante; 2021; [cited 2021 May 2]. Available from: https://www.has-sante.fr/upload/docs/evamed/CNEDIMTS-6294_EDWARDS_SAPIEN3_16_03_2021_(6294)_avis.pdf.